Portfolio

The Next Generation
of Innovators

All

Biotech | Exited/Public

Gene therapy company developing next-generation AAV vectors

medtech | Current

Integrated embolic protection systems

Biotech | Exited/Public

Treatement for the root cause of transthyretin amyloidosis

medtech | Exited/Public

Transforming the vascular closure market

medtech | Current

Transcervical treatment for symptomatic uterine fibroids

medtech | Current

Transforming the treatment of heart failure

medtech | Exited/Public

First fully implantable treatment for sleep apnea

MEDtech | CURRENT

Negative pressure device to treat postpartum hemorrhage

medtech | Current

Bio-engineered implant for ACL resotration

biotech | Exited/Public

Rationally designed small molecule protein degraders

medtech | Current

Novel treatment for chronic pain in lower limb amputees

medtech | Current

Innovative neuromodulation therapy for severe migraine headaches

MEDtech | Current

Innovative artificial cervical disc replacement device

biotech | Current

Precision therapies for genetic heart diseases

Medtech | Current

Non-invasive treatment of solid tumors

MEDTECH

medtech | Current

Integrated embolic protection systems

medtech | Exited/Public

Transforming the vascular closure market

medtech | Current

Transcervical treatment for symptomatic uterine fibroids

medtech | Current

Transforming the treatment of heart failure

medtech | Exited/Public

First fully implantable treatment for sleep apnea

medtech | Current

Negative pressure device to treat postpartum hemorrhage

medtech | Current

Bio-engineered implant for ACL resotration

medtech | Current

Novel treatment for chronic pain in lower limb amputees

medtech | Current

Innovative neuromodulation therapy for severe migraine headaches

medtech | Current

Innovative artificial cervical disc replacement device

Medtech | Current

Non-invasive treatment of solid tumors

BIOTECH

Biotech | Exited/Public

Gene therapy company developing next-generation AAV vectors

Biotech | Exited/Public

Treatement for the root cause of transthyretin amyloidosis

biotech | Current

Precision therapies for genetic heart diseases

biotech | Exited/Public

Rationally designed small molecule protein degraders

CURRENT

medtech | Current

Integrated embolic protection systems

medtech | Current

Transcervical treatment for symptomatic uterine fibroids

medtech | Current

Transforming the treatment of heart failure

medtech | Current

Negative pressure device to treat postpartum hemorrhage

medtech | Current

Bio-engineered implant for ACL resotration

medtech | Current

Novel treatment for chronic pain in lower limb amputees

medtech | Current

Innovative neuromodulation therapy for severe migraine headaches

MEDtech | Current

Innovative artificial cervical disc replacement device

biotech | Current

Precision therapies for genetic heart diseases

Medtech | Current

Non-invasive treatment of solid tumors

EXITED/PUBLIC

Biotech | Exited/Public

Gene therapy company developing next-generation AAV vectors

Biotech | Exited/Public

Treatement for the root cause of transthyretin amyloidosis

medtech | Exited/Public

Transforming the vascular closure market

medtech | Exited/Public

First fully implantable treatment for sleep apnea

Biotech | Exited/Public

Rationally designed small protein degraders

Please note that this list includes only private company investments and excludes any public company investments.

© 2024 Amzak Health | Privacy Policy | Luxury Marketing Mediaboom

category

Biotech

Status

Exited/Public

headquarters

Emeryville, California

website

Visit Website ›

4D Molecular Therapeutics

4D Molecular Therapeutics is a gene therapy company developing next-generation AAV vectors. The company’s proprietary Therapeutic Vector Evolution platform harnesses the power of natural selection to create customized AAV vectors that are designed to provide tissue targeted gene delivery, efficient transduction, reduced immunogenicity and resistance to pre-existing antibodies. 4DMT’s initial products target patients suffering from Fabry disease, X-linked Retinitis Pigmentosa, and Choroideremia.

category

Medtech

Status

Current

headquarters

Raleigh, North Carolina

website

Visit Website ›

Contego Medical

Contego Medical is a medical device company dedicated to the development of novel medical devices for neurovascular, cardiovascular and peripheral vascular procedures. The company’s Integrated Embolic Protection (IEP) platform, which combines embolic protection and treatment into one device, is designed to simplify catheter-based procedures and improve patient outcomes.

category

Biotech

status

Exited/Public

headquarters

Palo Alto, CA 

website

Visit Website ›

Eidos Therapeutics

Eidos Therapeutics is developing a novel drug to treat all forms of transthyretin (TTR) amyloidosis, a condition characterized by toxic amyloid aggregates in the heart and peripheral nerves. The lead candidate, AG10 is an orally-administered, small molecule designed to mimic a naturally-occurring genetic rescue mutation that protects high-risk individuals from developing TTR amyloidosis. Eidos was acquired by BridgeBio Pharma.

category

Medtech

status

Exited/Public

headquarters

Wayne, PA

website

Visit Website ›

Essential Medical

Essential Medical is a medical technology company developing best-in-class vascular closure devices for femoral punctures following cardiac catheterization procedures. These procedures, such as TAVR and EVAR, are some of the fastest growing segments within interventional cardiology, highlighting the need for fast, easy and uncomplicated arterial closure solutions. The company was acquired by Teleflex in 2018.

category

MEDTECH

status

Current

headquarters

Redwood City, California

website

Visit Website ›

Gynesonics

Gynesonics is a medical device company committed to advancing women’s health by developing transcervical, uterus-preserving, incisionless technologies for diagnostic and therapeutic applications. The company’s Sonata system is the world’s first and only intrauterine fibroid ablation system clinically proven to reduce fibroid symptoms across a wide range of fibroid types, sizes, and uterine locations.

category

Medtech

status

Current

headquarters

Marlton, NJ

website

Visit Website ›

Impulse Dynamics

Impulse Dynamics is a fast-growing medical device company that has pioneered a new form of therapy for heart failure called Cardiac Contractility Modulation, or CCM TM, which is delivered by the company’s Optimizer® Smart System. CCM is first-of-a-kind, FDA approved, life-changing treatment for a large population of heart failure patients with limited treatment options.

category

Medtech

status

Exited/Public

headquarters

Golden Valley, MN 

website

Visit Website ›

Inspire Medical Systems

Inspire Medical Systems, Inc. (NYSE: INSP) developed the world’s first fully implantable neurostimulation system for treatment of obstructive sleep apnea. The device works by opening up the upper airway in synchrony with patient’s breathing during sleep through gentle stimulation of the key airway muscles. It offers a safe, effective and minimally invasive alternative to millions of patients who have failed or are intolerant of Continuous Positive Airway Pressure (CPAP).

category

medtech

status

Current

headquarters

malvern, pennsylvania

website

Visit Website ›

KOKO Medical Inc.

KOKO Medical Inc. is a clinical stage medical device company committed to saving the lives of mothers with innovative products that allow for rapid postpartum hemorrhage intervention. It’s lead product, the Koko device, is currently in clinical testing.

category

Medtech

status

Current

headquarters

Westborough, Massachusetts

website

Visit Website ›

Miach Orthopaedics

MIACH Orthopaedics, Inc. is a medical technology company developing innovative bio-engineered surgical implants for connective tissue repair. The company’s initial focus is on the Bridge-Enhanced® ACL Repair (BEAR®) technology as a viable high performance alternative to conventional ACL reconstruction using grafts. The BEAR implants is the first medical technology to clinically demonstrate healing of a torn ACL and is the first new treatment for ACL in over 30 years. The BEAR technology was pioneered by Martha Murray, M.D., at the Boston Children’s Hospital Department of Orthopaedic Surgery.

category

Biotech

status

Exited/Public

headquarters

Boston, MA

website

Visit Website ›

Monte Rosa Therapeutics

Monte Rosa is developing a portfolio of novel molecular glue degrader precision medicines.  These treatments employ the body’s natural mechanisms to selectively eliminate therapeutically relevant proteins.  The company has developed a proprietary platform called QUEEN that enables it to rapidly identify protein targets and molecular glue product candidates.  Monte Rosa hopes to deliver pioneering therapies for cancer and beyond.

category

Medtech

status

Current

headquarters

Willoughby Hills, OH 

website

Visit Website ›

Neuros Medical

Neuros Medical is a medical device company that uses novel neuromodulation technology to treat patients suffering from chronic pain. The Altius System is a novel High-Frequency Nerve Block system to aid in the management of chronic intractable pain of the lower limb of adult amputees. The FDA designated Altius a Breakthrough Device. Chronic post-amputation pain is an area of significant unmet medical need with poor existing treatment options.

category

Medtech

status

Current

headquarters

Brooklyn Park, Minnesota

website

Visit Website ›

Shiratronics

ShiraTronics is an emerging medical device company developing an innovative neuromodulation approach to treat refractory migraine headaches. Migraines are a disabling disorder affecting millions of patients globally.

category

medtech

status

Current

headquarters

louisville, colorado

website

Visit Website ›

Synergy Spine

Synergy Spine is a medical device company that is at the forefront of innovation in spine technologies. The company’s flagship product, the Synergy Disc, is the first and only disc specifically designed to restore both alignment and balance while preserving physiologic motion for patients with degenerative disc disease. The Synergy Disc is currently commercially available in Asia, Australia, Canada, Europe, and New Zealand. In the United States, the Synergy Disc 1-level IDE trial completed enrollment in June 2023 and is currently enrolling patients for a 2-level trial.

category

Biotech

status

Current

headquarters

Quebec, Canada

website

Visit Website ›

Thryv Therapeautics

Thryv Therapeutics is advancing a pipeline of first in class SGK1 inhibitors to improve the lives of people suffering from Long QT Syndrome and certain resistant cancers.  Long QT Syndrome is a rare genetic disorder that can cause unexpected and life threatening arrhythmias.  The company’s initial focus is on developing small molecule inhibitors of a novel kinase responsible for electrical and mechanical remodeling of ion channels that may cause Long QT Syndrome.

category

medtech

status

Current

headquarters

Plymouth, Minnesota

website

Visit Website ›

HistoSonics

HistoSonics has developed a system to destroy tumors completely non-invasively. Treatment is achieved using histotripsy, a novel form of energy that is safe, extremely precise, and able to be personalized for each patient. The initial indication is for treatment of liver tumors and the system is being studied in several other types of tumors.